Your browser doesn't support javascript.
loading
HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol.
Mccafferty, Kieran; Caplin, Ben; Knight, Sinead; Hockings, Paul; Wheeler, David; Fan, Stanley L; Hulthe, Johannes; Kleta, Robert; Ashman, Neil; Papastefanou, Vasilios; Mehta, Hemal; Salama, Alan; Hadzovic, Sinela; Chowdhury, Tahseen Ahmad; Jarl, Lisa; Unwin, Robert; Challis, Benjamin; Sundgren, Anna K; Yaqoob, Muhammad Magdi.
Afiliación
  • Mccafferty K; Department of Nephrology, Barts Health NHS Trust, London, UK.
  • Caplin B; Centre for Nephrology, University College London Medical School, London, UK.
  • Knight S; Department of Discovery Biology, Discovery Sciences, R&D, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, UK.
  • Hockings P; Antaros Medical, Gothenburg, Sweden.
  • Wheeler D; MedTech West, Chalmers University of Technology, Goteborg, Sweden.
  • Fan SL; Centre for Nephrology, University College London Medical School, London, UK.
  • Hulthe J; Department of Nephrology, Barts Health NHS Trust, London, UK.
  • Kleta R; Antaros Medical, Gothenburg, Sweden.
  • Ashman N; Divison of Medicine, University College London, London, UK.
  • Papastefanou V; Department of Nephrology, Barts Health NHS Trust, London, UK.
  • Mehta H; Barts Health NHS Trust, London, UK.
  • Salama A; Royal Free Hampstead NHS Trust, London, London, UK.
  • Hadzovic S; Divison of Medicine, University College London, London, UK.
  • Chowdhury TA; Department of BioPharma Early Biometrics and Statistical Innovation, AstraZeneca, Goteborg, Sweden.
  • Jarl L; Department of Diabetes and Metabolism, Barts Health NHS Trust, London, UK.
  • Unwin R; Antaros Medical, Gothenburg, Sweden.
  • Challis B; Department of Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, UK.
  • Sundgren AK; Department of Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, UK.
  • Yaqoob MM; Department of Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
BMJ Open ; 10(9): e033923, 2020 09 09.
Article en En | MEDLINE | ID: mdl-32912939
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Nefropatías Diabéticas Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: BMJ Open Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Nefropatías Diabéticas Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: BMJ Open Año: 2020 Tipo del documento: Article